PriceTargets.com logo

Capricor Therapeutics - CAPR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 379.04%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.01 As of 04/19/2024 01:00 AM ET
▼ -0.04 (-0.79%)

This chart shows the closing price for CAPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Capricor Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAPR

Analyst Price Target is $24.00
▲ +379.04% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $24.00, with a high forecast of $40.00 and a low forecast of $8.00. The average price target represents a 379.04% upside from the last price of $5.01.

This chart shows the closing price for CAPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Capricor Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00Low
1/5/2024Cantor FitzgeraldInitiated CoverageOverweight$8.00Low
10/4/2023HC WainwrightBoost TargetBuy ➝ Buy$18.00 ➝ $40.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
3/16/2023HC WainwrightReiterated RatingBuy$18.00Low
10/26/2022LADENBURG THALM/SH SHInitiated CoverageBuy$15.00Low
1/31/2022HC WainwrightBoost TargetBuy$14.00 ➝ $18.00Medium
10/11/2021HC WainwrightBoost TargetBuy$9.00 ➝ $14.00High
9/24/2021Maxim GroupInitiated CoverageBuy$12.00Medium
8/7/2020Maxim GroupInitiated CoverageBuy$12.00High
5/16/2020Maxim GroupInitiated CoverageBuy$12.00High
4/30/2020Maxim GroupReiterated RatingBuy$10.00High
3/20/2020Maxim GroupReiterated RatingBuy$4.00High
3/19/2020HC WainwrightReiterated RatingBuy$9.00High
2/3/2020Maxim GroupUpgradeHold ➝ BuyHigh
1/21/2020HC WainwrightReiterated RatingBuy$9.00Medium
10/11/2019HC WainwrightReiterated RatingBuy$19.50Low
8/7/2019Maxim GroupReiterated RatingHoldHigh
7/15/2019HC WainwrightBoost TargetBuy$3.50 ➝ $12.40High
5/14/2019HC WainwrightSet TargetBuy$4.00High
5/1/2019HC WainwrightReiterated RatingBuy$3.50Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/19/2024
  • 6 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Capricor Therapeutics logo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Read More

Today's Range

Now: $5.01
Low: $4.87
High: $5.28

50 Day Range

MA: $5.52
Low: $3.61
High: $7.10

52 Week Range

Now: $5.01
Low: $2.68
High: $8.22

Volume

354,006 shs

Average Volume

286,540 shs

Market Capitalization

$157.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Capricor Therapeutics?

The following equities research analysts have issued reports on Capricor Therapeutics in the last twelve months: Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for CAPR.

What is the current price target for Capricor Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Capricor Therapeutics in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 375.2%. HC Wainwright has the highest price target set, predicting CAPR will reach $40.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $8.00 for Capricor Therapeutics in the next year.
View the latest price targets for CAPR.

What is the current consensus analyst rating for Capricor Therapeutics?

Capricor Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CAPR will outperform the market and that investors should add to their positions of Capricor Therapeutics.
View the latest ratings for CAPR.

What other companies compete with Capricor Therapeutics?

Other companies that are similar to Capricor Therapeutics include Alimera Sciences, Greenwich LifeSciences, 23andMe, Gossamer Bio and Trevi Therapeutics. Learn More about companies similar to Capricor Therapeutics.

How do I contact Capricor Therapeutics' investor relations team?

Capricor Therapeutics' physical mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company's listed phone number is 310-358-3200 and its investor relations email address is [email protected]. The official website for Capricor Therapeutics is www.capricor.com. Learn More about contacing Capricor Therapeutics investor relations.